---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-23-006898"
form_type: "8-K"
ticker: "COSM"
cik: "0001474167"
company_name: "Cosmos Health Inc."
filed_at: "2023-09-14T23:59:59+00:00"
generated_at: "2026-06-10T17:32:04.715738+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cosmos Health targets FY2026 revenue >$180M and EBITDA >$20M; recaps 2023 milestones

## Summary
- Inaugural 2026 guidance: gross annual revenue over $180M and EBITDA exceeding $20M.
- Completed three acquisitions in 2023: Cana Laboratories, I. Bikas GP assets, and ZipDoctor telehealth.
- Nutraceutical brands Sky Premium Life and Mediterranation expanding into new sales channels and geographies.
- Maintains robust balance sheet with negligible debt; CEO's personal investment now exceeds $15M.
- Second phase of obesity product CCX0722 completed; clinical trials scheduled to start in Q4 2023.

## SEC filing metadata
- accession: 0001477932-23-006898
- form_type: 8-K
- ticker: COSM
- cik: 0001474167
- company_name: Cosmos Health Inc.
- filed_at: 2023-09-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1474167/000147793223006898/0001477932-23-006898-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1474167/000147793223006898/cosm_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-23-006898
- JSON: https://secwatch.observer/filing/0001477932-23-006898.json
- Plain text: https://secwatch.observer/filing/0001477932-23-006898.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.